

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Application Number	Unassigned
Filing Date	December 13, 2006
First Named Inventor	William J. Dower
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	SPC-5199-USDIV1

[illegible]

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Dower et al.
Appln. No. : Unassigned
Filed : December 13, 2006
Title : PEPTIDES AND COMPOUNDS THAT BIND TO A RECEPTOR
Art Unit : Unassigned
Examiner : Unassigned

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**SUBMISSION OF FORM PTO-1449 AND NOTICE
OF REFERENCES CITED BY THE EXAMINER**

Dear Sir:

Attached is a copy of Form PTO-1449 and a copy of Notice of References Cited for U.S. Application Serial No. 11/254,419, the parent to the above-captioned application. Given that this application is a divisional of an earlier application, Applicants submit that copies of the references need not be submitted in order for the examiner to consider the prior art cited. See MPEP § 609 and § 2001.06(b).

If there are any other fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 10-0750/ SPC-5199-USDIV1/LAD.

Respectfully submitted,

/Laura A. Donnelly/

By: _____

Laura A. Donnelly
Reg. No. 38,435

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1729

Dated: December 13, 2006

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. FK3065054		SERIAL NO. To be assigned	
				APPLICANT Dower et al.			
				FILING DATE Concurrently herewith		GROUP	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date if Appropriate
as	AA	5,143,854	9/1/92	Pirrung et al.			
	AB	5,270,170	12/14/93	Schatz et al.			
	AC	5,326,558	7/5/94	Turner et al.			
	AD	5,338,665	8/16/94	Schatz et al.			
	AE	5,384,331	1/24/95	Kogan et al.			
	AF	5,358,934A	10/25/94	Borovsky et al.			
	AG	5,141,851A	8/25/92	Brown et al.			
	AH	5,411,942A	5/2/95	Widmer et al.			
as	AI	5,932,546	8/99	Barrett et al.			
Continued on page 3							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
as	BA	WO 90/15070	12/13/90	PCT			
	BB	WO 91/07988	6/13/91	PCT			
	BC	WO 91/08752	6/27/91	PCT			
	BD	WO 93/25221	12/23/93	PCT			
	BE	WO 95/11922	5/4/95	PCT			
	BF	WO 95/18858	7/13/95	PCT			
	BG	WO 95/21626	8/17/95	PCT			
	BH	WO 95/21919	8/17/95	PCT			
	BI	WO 95/21920	8/17/95	PCT			
	BJ	WO 95/28907	11/2/95	PCT			
	BK	EP 0 668 352 AI	2/14/95	EPO			
	BL	EP 0 675 201 AI	3/30/95	EPO			
	BM	EP 0 690 127 AI	1/3/95	EPO			
	BN	GB 2 285 446 A	7/12/95	GB			
	BO	WO 96/17062	6/6/96	PCT			
	as	BP	WO 96/17067	6/6/96	PCT		
BQ		WO 96/17062 AI	6/6/96	PCT			
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
as	CA	Barker et al., "Cyclic RGE peptide analogues as antiplatelet antithrombotics", J. Med. Chem., Vol. 35:2040-2048 (1992)					
as	CB	Bartley et al., "Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl", Cell, Vol. 77:1117-1124 (1994)					
as	CC	Bazan, "Structural design and molecular evolution of a cytokine receptor superfamily", Proc. Natl. Acad. Sci. USA, Vol. 87:6934-6938 (1990)					
Continued on page 2							

6/21/96

BEST AVAILABLE COPY

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO. PK3065US4	SERIAL NO. To be assigned
		APPLICANT Dower et al.	
		FILING DATE Concurrently herewith	GROUP
ay	CD	Caras et al., "Signal peptide for protein secretion directing glycopospholipid membrane anchor attachment", Science, Vol. 243:1196-1198 (1989)	
	CE	Cwirla et al., "Peptides on phage: A vast library of peptides for identifying ligands", Proc. Natl. Acad. Sci. USA, Vol. 87:6378-6382 (1990)	
	CF	Dexter et al., "Growth factor-dependent hemopoietic precursor cell lines", J. Exp. Med., Vol. 152:1036-1047 (198)	
	CG	Dower et al., "The search for molecular diversity (II): Recombinant and synthetic randomized peptide libraries", Ann. Rep. Med. Chem., Vol. 26:271-280 (1991)	
	CH	Dower et al., "High efficiency transformation of E.coli by high voltage electroporation", Nucleic Acids Research, Vol. 16:6127 (1988)	
	CI	Fodor et al., "Light-directed, spatially addressable parallel chemical synthesis", Science, Vol. 251:767-773 (1991)	
	CJ	Harker, "Kinetics of thrombopoiesis", J. Clin. Invest., Vol. 47:458-465 (1968)	
	CK	Kaushansky et al., "Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin", Nature, Vol. 369:568-571 (1994)	
	CL	Kojima et al., "Molecular cloning and expression of megakaryocyte potentiating factor cDNA", J. Biol. Chem., Vol. 270:21984-21990 (1995)	
	CM	Kuter et al., "The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production", Proc. Natl. Acad. Sci. USA, Vol. 91:11104-11108 (1994)	
	CN	McDonald, "Thrombopoietin - its biology, clinical aspects and possibilities", Am. J. Pediatric Hematology/Oncology, Vol. 14:8-21 (1992)	
	CO	Metcalfe, "Thrombopoietin - at last", Nature, Vol. 369:519-520 (1994)	
	CP	Methia et al., "Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis", Blood, Vol. 82:1395-1401 (1993)	
	OQ	Mossmann, "Rapid colorimetric assays for cellular growth and survival: Application to proliferation and cytotoxicity assays", J. Immunol. Methods, Vol. 65:55-63 (1983)	
	CR	Or et al., "Cysteine alkylation in unprotected peptides: Synthesis of a carbavosopressin analogue by intramolecular cysteine alkylation", J. Org. Chem., Vol. 56:3146-3149 (1991)	
	CS	de Sauvage et al., "Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand", Nature, Vol. 369:533-538 (1994)	
	CT	Souyri et al., "A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors", Cell, Vol. 63:1137-1147 (1990)	
	CU	Vigon et al., "Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: Identification of a member of the hematopoietic growth factor receptor superfamily", Proc. Natl. Acad. Sci. USA, Vol. 89:5640-5644 (1992)	
	CV	Verber et al., "The design of metabolically-stable peptide analogs", Trends in Neurosciences (TINS), pgs. 392-396 (1990)	
	CW	Wendling et al., "The oncogene V-MPL, A putative truncated cytokine receptor which immortalizes hematopoietic progenitors", L'Inserm, pgs. 145-146 (1992)	
	CX	Wendling et al., "c-Mpl ligand is a humoral regulator of megakaryocytopoiesis", Nature:571-574 (1994)	
	CY	Kato et al., "Purification and Characterization of Thrombopoietin", J. Biochem., Vol. 118:229-236 (1995)	
os	CZ	Wada et al., "Characterization of the Truncated Thrombopoietin Variants", Biophysical Research Communications, Vol. 213:1091-1098 (1995)	
EXAMINER		DATE CONSIDERED 6/2/96	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			

BEST AVAILABLE COPY

To be Assigned

Concurrently Herewith

DOWER et al.

11/11/2016

--	--

PK3065US4

**Examiner
Initials**

Issue Date

Name _____

Class

Subclass

**Filing Date
If
Appropriate**

22

AJ
AK

5,869,451
6,083,913

02-1999
07-2000

DOWER et al.
DOWER et al.

514
514

13	
13	

FOREIGN PATENT DOCUMENTS

**Document
Number**

**Publication
Date**

Country

Class

Subclass

Translation:
Yes | No

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

EXAMINER

Continue on page

DATE CONSIDERED _____

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Notice of References Cited	Application/Control No. 11/254,419	Applicant(s)/Patent Under Reexamination DOWER ET AL.	
	Examiner Anish Gupta	Art Unit 1654	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-2005/0137133	06-2005	MacDonald et al.	514/012
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(e).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.